Summary
This study was designed to determine the feasibility of identifying those patients with chronic heart failure who will be improved by dobutamine infusion. Twenty-two patients with stable heart failure were treated by infusion of an average dobutamine dose of 12.5 ng/kg/min for 36 hours, then again during a 4-hour session once a week for 1 month. Patients were evaluated by clinical, ergometric, and biochemical parameters (plasma norepinephrine and lymphocyte beta-receptor density) before and after every infusion. Hemodynamics were assessed before and during the first dobutamine infusion.
A test with isoproterenol was performed prior to the start of dobutamine therapy. All patients exhibited hemodynamic improvement, which peaked at the 12th hour (55% increase in the cardiac index [p<0.01]; 35% reduction in the filling pressure and systemic arterial resistance).
Five patients stopped the study prematurely. Nine patients (group 1) were clinically improved according to their NYHA classification. Eight patients (group 2) remained stable or had progressive disease. The lymphocyte beta-receptor density before dobutamine infusion was significantly higher in group 1 than in group 2 (66±12 vs. 46.7±18 fM/mg; p<0.01). Finally, a good correlation (p<0.05) was observed between the beta-receptor level and the isoproterenol dose required to obtain a heart rate of 130 beats/min.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure.Circulation 1977;56:468–472.
Liang CS, Sherman LG, Doherty JU, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine.Circulation 1984;69:113–119.
Unverferth DV, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after 72 hours continuous infusion.Am J Med 1980;69:113–119.
Unverferth DV, Magorien RD, Altschuld R, et al. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy.Am Heart J 1983;106:29–34.
Leier CV, Huss P, Lewis RP, Unverferth DV. Drug-induced conditioning in congestive heart failure.Circulation 1982;65:1382–1387.
Colucci WS, Wright RF, Braunwald E. New position inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical development.N Engl J Med 1986;314:296–299.
Hoyer D, Engel G, Berthold R. Binding characteristics of (+), (±), a,d (−)-(125 idocyanopindolol) in guinea pig left ventricle membranes.Naunyn Schmiedeberg's Arch Pharmacol 1982;31:319–320.
Maskin CS, Forman R, Sonnenblick EH, et al. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure.Am J Cardiol 1983;51:177–182.
Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts.N Engl J Med 1982;307:205–211.
Anderson KE. Adrenergic mechanism in congestive heart failure.Acta Med Scand 70 (Suppl) 1986;37–44.
Bristow MR, Ginsburg R, Gilbert EM, Hershberger RE. Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart.Basic Res Cardiol 1987;82(Suppl 2):369–376.
Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response.Circulation 1986;74:1290–1302.
Brodde OE, Schüler S, Kretsch R, et al. Regional distribution of β-adrenoceptors in the human heart: Coexistence of functional β-1 and β-2 adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy.J Cardiovasc Pharmacol 1986;8:1235–1242.
Bristow MR, Ginsburg R, Umans V, et al. β-1 and β-2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure.Circ Res 1986;59:297–309.
Colucci WS, Alexander W, Williams GH, et al. Decreased lymphocyte beta-adrenergic density in patients with heart failure and tolerance to the beta agonist pirbuterol.N Engl J Med 1981;305:185–190.
Drici M, Sbirrazuoli V, Gibelin P, et al. Beta-adrenoceptor evaluation in cardiovascular pharmacology: Correlation between receptors in human myocardium and corresponding circulating lymphocytes (abstract).Cardiovasc Drugs Ther 1987;1:230.
Gordon EP, Bristow MR, Laser GA, et al. Correlation between β-adrenergic receptors in human lymphocytes and heart (abstract).Circulation 1983;68(Suppl III):99.
Brodde OE, Michel MC, Gordon EP, et al. β-adrenoceptor regulation in the human heart: Can it be monitored in circulating lymphocytes?Eur Heart J 1989:10:2–10.
Rasmussen R, Shah P, Carrabee P, et al. β1 and β2 receptor down-regulation associated with β-agonist administration in the failing human heart (abstract).Circulation 1987;76 (Suppl IV):306.
Mancini DM, Frey MJ, Fischberg D, et al. Characterization of lymphocyte beta-adrenergic receptors at rest and during exercise in ambulatory patients with chronic congestive heart failure.Am J Cardiol 1989;63:307–312.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gibelin, P., Sbirrazzuoli, V., Drici, M. et al. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. Cardiovasc Drug Ther 4, 1105–1111 (1990). https://doi.org/10.1007/BF01856506
Issue Date:
DOI: https://doi.org/10.1007/BF01856506